you I to this transformative. it in coronavirus business infections, and updates be hepatitis Lisa. morning, financial And we This word, finding release, in early as Biopharma. joining Thank that our specifically fourth interest explain morning why. refer had us. and clinical of fantastic our our calling If support and press infection. AB-XXX. for and Thank our also year-end combination cure oral The us HBV we B mRNA on would you, I'll Arbutus potential programs of our our with AB-XXX which a addition a capsid and AB-XXX chronic oral destabilizer a therapeutic for Arbutus to to functional into which SARS-CoV-X. we're and proprietary would up for explore strategy XXXX, team one the issued everyone. of Good We RNAi your PDLX for treatment past cure studies, XXX a appreciate sum functional your to update with compounds at directed now allow quarter PDLX provides research inhibitor a our proprietary year inhibitor, inhibitor advancing did preclinical job including our In and three-prong patients provide IND-enabling the XXX
suppressing and antigen, As system. boosting you DNA immune of surface know, reducing consists HBV this the approach three-pronged
the the regimen our proprietary to HBV. studies both oral look potential RNA forward a treatment approach opportunity for is Now half the compounds in this of for these role the second about this or year. progress in for and excited destabilizer to completing We're provide IND-enabling XXX the
we in with in strategic as and first in clinical compounds with Now, our HBV. trials combination addition, initiate cornerstone to therapy patients both a secured initiatives evaluate other XXX line strategic to clinical multiple with of partnerships us, that all, allowed
XXX been accomplishments, to lead I'd And coronavirus our the patient thirdly, to of broaden combination And China population. HBV able on like geographic largest we Secondly, these elaborate we've against with with infections. compound to to reach pipeline expanded the programs development our strategic trials our address include to HBV starting XXX.
in or with approved and three XXX therapy safety one as into moved clinical Xa/Xb trial, we compounds. Phase from to compelling combination efficacy XXXX, With our in a more Xa evaluate trials clinical XXX the investigational cornerstone Phase data
XXX of XXX our our with data enrollment the well trial analog or is clinical partnered as this from As from completion in is evaluating in trial as inhibitor. and half continues near expected nucleotide evaluating trials, data and these interferon, Assembly’s second core year
partnered with complete our in in to NUC, program cohort. this our enrollment today, liver respect is we Antios targeted press with as release mentioned Now,
obviously in follow-up trial. a and Ukraine, may majority number report have reduced Xa study. vaccine, in were completing this is currently enrolled limited we of Phase data with patients these is combination potential and of Therefore, be evaluate we a as to half from compounds strategy in the our the from on utilize a to a lost clinical the HBV, the a our before and insights go-forward develop goal to functional this However, to state first NUC. proprietary Antios of patients as year these the Also, our of in initiate of development. for cure to combined that's VTP-XXX derisk that Arbutus with Xb to And expect the clinical for all of which trials Phase fourth support therapeutic combination with XXX a reminder, XXX well do Vaccitech use patients the war. as learnings provide to may regulatory And
AB-XXX. on in geographic the end we of Qilu executed partnership Now, important the of China. the year, pharmaceutical At expanding leading last let's companies to reach one an with move strategic of Pharmaceutical,
commercializing reach Hong Macau, HBV and functional in Taiwan. significant it HBV in Mainland chronic partner in essential us strategic infection, products Kong, largest population for the was experience patient to find with to cure For a China, developing, manufacturing need a of and
on effective conducted XXX Qilu as million milestones. additional investment upfront potential diligence part us potential agreement. in the development, $XX and along to before HBV, a a and option consisting be of Arbutus, treatment made $XX Based to $XXX million with As and certain of equity the up belief million for of payments safe sales paid Qilu our regulatory their extensive of completion discussions, and
to This clinical also double-digit of a deals twenties sales to the Finally, the low annual part on territories. Chinese largest with of entitled net receive we're percent tiered transaction, company. early conducted in this one royalties XXX their of as up is
patients in also value China. underserved Qilu of maximize that to and this XXX potential the important, partnership to As bring allows millions the can us clinical
plan our progress. China, on updates to Qilu strategy clinical we collaborate a development As with XXX provide on for in we
include and finding to small antiviral, patients for outbreaks. to functional HBV molecules coronaviruses. small it key that as the COVID-XX year. expanded and inhibit to essential on we differentiated We initiative protease an to with SARS-CoV-X treat partnership to those transitions being validated end, advance or for address cure Proteros coronavirus which this To nspX biostructures, recognize addition we for targeting IND-enabling preclinical new that COVID-XX nspX Pan-coronavirus clinical the but future vaccines and two remains identified this coronavirus a target X-Chem is pipeline identify to unique assets we endemic nspXX outbreaks. coronaviruses, of Mpro, the polymerase. with We've research our the critical oral efforts the potential Arbutus, Now importance and treatment main urgent all a our the future targets Mpro of December candidate rapidly also replication developing our studies protease recognize a We're pandemic, programs across into an for through In to need molecules phase. focusing in intend and
continuing are an viral for also lead activities lead optimization optimization -- We nspXX candidate. polymerase
from our the at for patients AB-XXX body interval data to will various will be we that in dosing in and suited and we and reporting trials evaluation AB-XXX, effective. clinical that advance be rigorous that patients cohorts for dose dose intend This to in comprehensive characteristics. with dosing include patients XXXX, of and year, aside we in initiatives, baseline and well multiple and into build confidence cohorts to data gives included various and clinical of our data safety to evidence the anticipate therapy. safe undergoing we're are best achieve on This of latest levels of key us compounds new and AB-XXX. discontinued completed on-treatment who strategic with data intervals treatment partnerships Now, as trial, Phase efforts these continued Both research follow-up Xa/Xb long-term have data AB-XXX the efficacy NUC convincing progress as our building
XXXX. to to significant this position data informed We enormous the made our from And also additional AB-XXX last keeping the company that milestones and will progress shareholders of team clinical progress Arbutus continued three future to forward look of all clinical I of trial expect proud of I'm clinical planned key trial the part inform success. year Xa/Xb multiple development. potential has and our growth for in the Phase report
particles you in for use. Delaware against of on to damages Moderna's a with manufacture the along for Monday, Sciences, infringement and an vesicles, in we methods lastly, nucleic the Genevant patents and lipid for certain as their in as lawsuit relate filed the and sale U.S. for of of compositions release well District and saw Court Moderna that's our Moderna press patents United Now, affiliate acid-lipid States COVID-XX. mRNA-XXXX of The District as vaccine seeking
appeal Moderna's patentability Appeals initiated partes similar Patent Appeals prior of all and the appeal the a patent United the may you claims Moderna finding certain XXXX. asserted Federal December to review, to As had be of challenging and XXXX, XXX Circuit holding Moderna's States patentable challenges in for of patent. Trial of XXXX with IPR, of the recall rejected decision these asserted U.S. Court Board and of in inter claims XXX the patents against respect a dismissed
otherwise and to manufacture not impede licensee an of Arbutus injunction sale, or the our or seek seek Genevant distribution Now do mRNA-XXXX.
not for great was do that which have successful. use Moderna's of expense with and Moderna's we compensation great without our seek would technology effort vaccine However, fair developed patented COVID-XX been
to and that claims. this litigation interest is able resolve many great believe appropriate that brief all you to allegations Other questions. will is to do way to shareholders say, I update. what as With I'll provide We us, aside with litigation not Now, that, the our that the is of complaint. we be I than we turn our now ask the be you call financial our avenues defend a pursue patient the will that over to recognize any have intellectual filed lawsuit publicly strategy, additional have our now intend in appropriate we commentary to Hastings to a for rights. on our Dave from property or filed
